ASCA: Surgery Centers Receive Letters Warning About Compounded Drugs

Surgery centers have reported to ASCA that they have received letters from law firms representing drug manufacturers, warning about the use of compounded drug products over commercially produced drugs, according to an ASCA report.

Advertisement

ASCA has contacted the FDA to determine whether the statements in the letters are accurate. ASCA asks surgery centers receiving such letters to contact Steve Miller at smiller@ascassociation.org.

Related Articles About ASC Supply Chain:
Precision Spine Receives FDA Clearance for Minimally Invasive Access System
Lutronic Receives FDA Clearance for Phototherapy System
Ethicon Initiates Recall of Select Surgiflo Hemostatic Kits

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.